Anika Therapeutics 2025 Q3 Earnings Narrows Net Loss by 92.2%
Anika Therapeutics (ANIK) reported fiscal 2025 Q3 earnings on Nov 5, 2025, . The company narrowly beat revenue estimates and maintained full-year guidance, , marking a 122.22% beat.
Revenue
, while the Commercial Channel contributed $11.97 million, bringing the total to $27.82 million. , .
Earnings/Net Income
. The net loss reduced to $-2.33 million, . This marks a significant step toward profitability, though challenges persist in operational costs and R&D expenses.
Post-Earnings Price Action Review
.
CEO Commentary
The CEO emphasized navigating supply chain constraints and competitive pressures while investing in R&D for orthopedic and spine therapies. Regulatory progress and partnerships are expected to drive long-term growth, alongside cost discipline to mitigate near-term financial pressures.
Guidance
, . .
Additional News
Anika filed the final PMA module for Hyalofast with the FDA, including 24-month FastTRACK trial data and real-world evidence. , signaling confidence in its financial stability. .

Key Financial Highlights
Revenue.
Non-GAAP EPS.
Net Loss.
Full-Year Guidance,
Strategic Updates
Hyalofast PMA Filing.
Share Buyback.
R&D Focus.
Market Outlook
, . , .
Que la lista de los informes de ganancias de las compañías destacadas sea conocida después de que cierren las bolsas hoy, y antes de que abran las bolsas mañana.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments
No comments yet